Arbutus Biopharma/$ABUS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Arbutus Biopharma

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Ticker

$ABUS
Sector
Primary listing

Employees

44

ABUS Metrics

BasicAdvanced
$836M
-
-$0.29
1.01
-

Bulls say / Bears say

Combination therapy with imdusiran has functionally cured eight cHBV patients to date, including two who achieved cure without interferon, demonstrating strong antiviral activity in early-stage trials.
AB-101, the oral PD-L1 inhibitor, achieved 100% receptor occupancy at the 40 mg dose in 11 of 13 healthy volunteers without serious adverse events, showing robust target engagement and a favorable safety profile.
Arbutus has reacquired global rights to imdusiran in Greater China, ending its partnership with Qilu Pharmaceutical and regaining full control over commercial and clinical development of its lead asset.
Arbutus’ cash and marketable securities totaled $113 million at Q1 2025, which may be insufficient to fully fund its planned Phase 2b trial and continued development programs, raising the risk of future dilution.
Qilu Pharmaceutical’s decision to terminate its Greater China partnership for imdusiran indicates a reprioritization by the external partner and may highlight doubts regarding the compound’s market potential in that region.
AB-101 is still in Phase 1a/1b trials and no efficacy data in patients have been reported, maintaining clinical uncertainty and delaying key value milestones.
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ABUS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs